10X GENOMICS, INC. (TXG): Price and Financial Metrics
TXG Stock Summary
- With a one year PEG ratio of 0.84, 10x Genomics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 6.34% of US stocks.
- 10x Genomics Inc's stock had its IPO on September 12, 2019, making it an older stock than only 1.56% of US equities in our set.
- With a price/sales ratio of 71.12, 10x Genomics Inc has a higher such ratio than 95.42% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to 10x Genomics Inc, a group of peers worth examining would be NBIX, AZPN, YY, DLB, and OOMA.
- Visit TXG's SEC page to see the company's official filings. To visit the company's web site, go to www.10xgenomics.com.
TXG Stock Price Chart Interactive Chart >
TXG Price/Volume Stats
| Current price | $177.99 | 52-week high | $201.70 |
| Prev. close | $173.10 | 52-week low | $48.78 |
| Day low | $169.61 | Volume | 802,664 |
| Day high | $179.49 | Avg. volume | 745,419 |
| 50-day MA | $169.44 | Dividend yield | N/A |
| 200-day MA | $127.56 | Market Cap | 17.86B |
10X GENOMICS, INC. (TXG) Company Bio
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
Latest TXG News From Around the Web
Below are the latest news stories about 10x Genomics Inc that investors may wish to consider to help them evaluate TXG as an investment opportunity.
10x Genomics Showcases Next Wave of Innovations at First Ever Xperience EventAcquires Tetramer Shop; Reveals Details on Upcoming ProductsPLEASANTON, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today detailed a slew of new products and announced the acquisition of Copenhagen-based Tetramer Shop at its inaugural Xperience 2021 event, a showcase with three breakout sessions corresponding to 10x’s three product platforms: Chromium Single Cell, Visium Spatial, and In Situ Analysis. Tetramer Shop marks the fifth acquisition for 10x Genomics in its ongoing mission to master biology to advance human health. This acquisition follows the additions of epigenomics innovator Epinomics and spatial genomics pioneer Spatial Transcriptomics in 2018, as well as In Situ analysis companies CartaNA AB and ReadCoor in 2020. Tetramer Shop’s expertise in ... |
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2020 Results - Earnings Call Transcript10x Genomics, Inc. (TXG) Q4 2020 Results Conference Call February 17, 2021 04:30 PM ET Company Participants Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug Schenkel - Cowen Tejas Savant - Morgan Stanley Derik De Bruin - Bank... |
Why 10x Genomics' Soaring Q4 Revenue Wasn't Enough to Impress InvestorsIf you want evidence that investors are excited about genetic testing stocks, just take a look at 10x Genomics (NASDAQ: TXG). 10x Genomics announced its fourth-quarter and full-year 2020 results after the market close on Wednesday. 10x Genomics reported revenue in the fourth quarter of $112.2 million, a 49% year-over-year jump. |
10x Genomics EPS of -$3.8710x Genomics (TXG): Q4 EPS of -$3.87 may not be comparable to consensus of -$0.23.Revenue of $112.2M (+49.0% Y/Y) beats by $11.8M.2021 Financial Guidance: 10x Genomics expects full year 2021 revenue to be in the range of $480 million to $500 million, representing 61% to 67% growth over full year... |
10x Genomics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021Q4 2020 revenue growth of 49% over prior year PLEASANTON, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook for full year 2021. Recent Highlights Revenue was $298.8 million for the full year and $112.2 million for the fourth quarter of 2020, representing 22% and 49% increases over the corresponding periods of 20192,412 Chromium instruments sold as of December 31, 2020More than 2,200 peer-reviewed publications based on data generated using 10x productsOperations center in Singapore came online and began consumables manufacturing Fourth Quarter 2020 Financial Results Revenue was $112.2 million for the three months ended December 31, 2020, a 49% increa... |
TXG Price Returns
| 1-mo | 9.05% |
| 3-mo | 18.13% |
| 6-mo | 61.35% |
| 1-year | 144.73% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 25.70% |
| 2020 | 85.70% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...